skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8847

Distinguishing between attention-deficit hyperactivity and fetal alcohol spectrum disorders in children: clinical guidelines

Review

(3078) Views  (1787) Full article downloads

Authors: Elizabeth Peadon, Elizabeth J Elliott

Published Date August 2010 Volume 2010:6(1) Pages 509 - 515
DOI: http://dx.doi.org/10.2147/NDT.S7256

Elizabeth Peadon, Elizabeth J Elliott
Discipline of Paediatrics and Child Health, Sydney Medical School, University of Sydney, Sydney, Australia

Abstract: Fetal alcohol spectrum disorders (FASD) are the physical and neurodevelopmental outcomes of fetal alcohol exposure. The behavioral phenotype of children with FASD includes difficulties with executive function, memory, planning, processing speed, and attention. Although attention deficit hyperactivity disorder (ADHD) is diagnosed in up to 94% of individuals with heavy prenatal alcohol exposure, the exact relationship between FASD and ADHD is unclear. There is some evidence that ADHD in FASD may be a specific clinical subtype and thus may require a different treatment approach. Although traditional behavioral observation scales may not distinguish between the two groups, there is evidence that children with FASD have a different profile on the four-factor model of attention than children with ADHD who do not have FASD. There is a paucity of good scientific evidence on effective interventions for individuals with ADHD and FASD. There is weak evidence that children with FASD and ADHD may have a better response to dexamphetamine than methylphenidate. There is a strong need for larger, high quality studies to examine the relationship between ADHD and FASD and identify effective treatments because management of inattention and hyperactivity may improve learning and ameliorate the common secondary disabilities associated with FASD.

Keywords: fetal alcohol spectrum disorders, attention deficit hyperactivity disorder







Readers of this article also read:

Alogliptin: a new addition to the class of DPP-4 inhibitors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
Potential renovascular hypertension, space missions, and the role of magnesium
Critical appraisal of the role of glucosamine and chondroitin in the management of osteoarthritis of the knee
Ego mechanisms of defense are associated with patients’ preference of treatment modality independent of psychological distress in end-stage renal disease
Can a gentamicin-specific chart reduce neonatal medication errors?
Nephroprotective action of glycosaminoglycans: why the pharmacological properties of sulodexide might be reconsidered
Dashboards in neonatology
Everolimus-eluting stents: update on current clinical studies
Metabolic pathway and distribution of superparamagnetic iron oxide nanoparticles: in vivo study